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For these reasons we, and a number of other groups, have been evaluating the potential for gene therapy to overcome both the toxic and potentially carcinogenic side-effects of antitumour chemotherapy. [4] [5] [6] [7] [8] [9] [10] [11] [12] One candi-date gene for chemoprotection is multidrug resistance 1 (MDR1), which encodes a membrane transport glycoprotein able to reduce the intracellular levels of a number of amphiphilic antitumour agents substantially. 4 Transfer and expression of MDR1 in murine and human haemopoietic cells leads to protection against the toxic effects of agents such as vincristine, paclitaxel, colchicine and etoposide. 6, [13] [14] [15] [16] As a result of these studies, clinical trials of MDR1-based chemoprotective gene therapy were initiated, but success has been limited due to low transduction efficiencies in repopulating cells. 17, 18 Similarly, the DNA repair protein, O 6 -alkylguanine-DNA-alkyltransferase (ATase), has received much attention and we and others have reported protection of murine and human haemopoietic cells in vitro and in vivo from the biological effects of the clinical O 6 -alkylating agents.
7, [10] [11] [12] [19] [20] [21] [22] As with MDR1-based protection, ATasebased gene therapy will soon be tested in a clinical context.
The results of clinical trials of gene therapy with single resistance functions will be of great benefit in designing future drug treatments, and may lead to increased thera-peutic indices using current chemotherapeutic regimens. However, few treatment schedules rely on only one category of agent and most are comprised of combinations of drugs. While this helps to overcome tumour resistance to any single agent, the same may be true of resistance engineered in drug-sensitive tissues. For this reason, we have begun to examine the potential for creating diverse drug resistance profiles in otherwise sensitive cells, by combining different drug resistance factors in a single vector. Here, we report dual expression of MDR1 and ATase from a retroviral expression vector. For combined expression of both genes we chose the FMEV backbone, 14 previously shown to express MDR1 to levels required for high-dose drug resistance in primary human haemopoietic cells, 16 even when co-expressing a second gene besides MDR1.
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K562 cells have a combined potential for erythroid and monocytic differentiation and the validity of these cells for characterizing vectors that confer chemotherapy resistance to primary human haemopoietic progenitor cells was proven in earlier studies.
14,16,23 K562 cells exposed to SF1MIH retrovirus were selected for expression of MDR1 by growth in the presence of 20 ng/ml colchicine. No cell survival was seen in control, untransduced cultures under these conditions. However, when SF1MIH exposed cultures were challenged with 20 ng/ml colchicine, a population of drug-resistant cells was isolated, which grew exponentially under continuous selective pressure.
Expression of both MDR1 and ATase was determined by immunocytochemical analysis using the human MDR1-specific monoclonal antibody UIC-2 or a polyclonal antibody to human ATase. Control cells showed no evidence of MDR1 or ATase expression. In contrast, the K562-SF1MIH cells exhibited strong staining for MDR1, which was mainly confined to the plasma membrane, and intense nuclear staining for ATase (data not shown). In addition, the ATase activity (determined using a radiolabelled methylated DNA substrate 24 ) in control cells was undetectable (Ͻ2 fmol/mg protein), while the SF1MIH transduced, colchicine selected cells exhibited high (3000 fmol/mg protein) levels of ATase activity.
We next tested the sensitivity of control and K562-SF1MIH cells to killing by MDR1 substrate drugs in a colony-forming assay ( Figure 1a ). When control cells were plated in the presence of increasing doses of colchicine, the colony-forming efficiency dropped rapidly as a function of drug concentration. In contrast, however, cells expressing MDR1 as a consequence of transduction with SF1MIH were substantially less sensitive to the effects of colchicine, consistent with their initial selection with this drug. When the LD 50 for cell killing by colchicine was calculated for control and K562-SF1MIH cells (2 ng/ml and 53 ng/ml respectively), this showed that the latter were 26-fold more resistant to colchicine than the untransduced controls. Similar results were obtained when doxorubicin was included in the plating assays (Figure 1b) as the K562-SF1MIH cells were approximately 28-fold more resistant to this drug (LD 50 = 65 ng/ml) than the control cells (LD 50 = 2.3 ng/ml). Significantly, when the MDR1 antagonist verapamil was included in these experiments, the sensitivity of K562-SF1MIH cells to doxorubicin was markedly increased and the LD 50 was reduced more than 10-fold to 6 ng/ml, confirming that resistance to doxorubicin in the transduced cells was mediated through MDR1 expression.
Figure 1 Sensitivity of control and K562-SF1MIH cells to killing by colchicine and doxorubicin. (a) Percent colony formation (relative to no-drug controls) by untransduced K562 (᭺) and K562-SF1MIH (᭹) exposed to various doses of colchicine. (b) Percent colony formation (relative to nodrug controls) by untransduced K562 (᭺,̃) and K562-SF1MIH (᭹,̄) exposed to various doses of doxorubicin in the presence (̃,̄) and absence (᭺,᭹) of verapamil (5 m). Vector construction was as described
In order to determine if the K562-SF1MIH cells were also resistant to O 6 -alkylating agents, colony-forming assays were performed in the presence of increasing levels of either of the methylating agents MNU (Figure 2a ) or temozolomide (Figure 2b) . The K562-SF1MIH cells exhibited increased resistance to killing by either methylating agent when compared with control, untransduced cells. Thus transduced cells were at least 13-fold more resistant (LD 50 Ͼ20 g/ml) than equivalent control cells to killing by temozolomide (LD 50 = 1.5 g/ml) and 60-fold more resistant (LD 50 = 90 g/ml) than controls (LD 50 = 1.5 g/ml) to the toxic effects of MNU. That the resistance was ATase mediated was confirmed by prior exposure of the K562-SF1MIH cells to the potent ATase inactivator O 6 -beG: transduced cells were sensitised to temozolomide such that their susceptibility to killing approached that of untransduced cells (Figure 2b) .
Finally, control and K562-SF1MIH cells were tested for their sensitivity to killing following simultaneous exposure to MNU and colchicine. All control cells exposed to colchicine and MNU died. However, there was no difference in the sensitivity of K562-SF1MIH cells to increasing doses of MNU when plated in the presence or absence of colchicine (20 ng/ml; Figure 3) . Similarly, 26% of the K562-SF1MIH cells survived exposure to a combination of temozolomide (10 g/ml) and doxorubicin (10 ng/ml) that resulted in complete killing of control cells (data not shown).
There is presently much interest in protecting human bone marrow from the dose limiting toxicities of a variety of antitumour agents by expression of drug resistance proteins in primitive haemopoietic progenitors. There are a number of candidate resistance factors that are likely to be useful and among these, both MDR1 and ATase have been particularly well evaluated when expressed singly. However, in order to expand the overall importance of this approach, we have evaluated the utility of a dual expression retroviral vector to induce simultaneous expression of the two resistance functions in otherwise drug-sensitive cells. The cDNAs were combined via an IRES sequence from poliovirus, resulting in a bicistronic mRNA produced via the LTR. This strategy has previously been shown to guarantee reliable co-expression of a second gene in an FMEV:MDR1 vector. 23 The FMEV backbone was chosen because of the superior gene expression levels demonstrated in the primitive myeloid target cell population of interest, as evidenced by the observation that FMEV-based bicistronic MDR1 vectors were able to induce dominant multidrug-resistance in human haemopoietic progenitor cells. 23 The importance of using a strong vector backbone is underlined by the
Figure 2 Sensitivity of control and K562-SF1MIH cells to killing by MNU and temozolomide. (a) Percent colony formation (relative to nodrug controls) by untransduced K562 (᭺) and K562-SF1MIH (᭹) exposed to various doses of MNU. (b) Percent colony formation (relative to no-drug controls) by untransduced K562 (᭺,̃) and K562-SF1MIH (᭹,̄) exposed to various doses of temozolomide in the presence (̃,̄) and absence (᭺,᭹) of O
6 -beG (20 m). observation that translation efficiency mediated via the polio-IRES is up to one order of magnitude lower than cap-driven translation (Hildinger and Baum, unpublished data). In the absence of better co-expression strategies, this loss of translation efficacy for the IREScontrolled gene must be compensated for by the transcriptional activity of the vector. Transduction of K562 cells allowed them to be selected on the basis of their resistance to the MDR1 substrate colchicine, whereas no resistant cells could be derived from untransduced cultures. Analysis of the colchicine-resistant cells showed that they had highly enhanced levels of ATase compared with their untransduced counterparts and immunocytochemistry showed expression of both MDR1 and ATase in transduced, but not untransduced cells. Importantly, the two proteins were located separately in the cells, MDR1 at the cell membrane and ATase in the nucleus, showing correct localisation and confirming the production of two separate proteins from the same vector genome. Functionally both proteins were able to confer drug resistance against a range of appropriate antitumour agents. Furthermore, that this protection was due to expression of the appropriate resistance functions was demonstrated by reversal of the resistance phenotype to doxorubicin and temozolomide, using the MDR1 antagonist verapamil and the ATase inactivator O 6 -beG, respectively. Finally, it was possible to demonstrate resistance to a combination of an MDR1 substrate drug (doxorubicin or colchicine) and an O 6 -alkylating agent (temozolomide or MNU) at concentrations where unprotected cells were completely killed.
The potential clinical benefits of the data reported are evident: using dual (or even triple) expression vectors it should prove possible to provide substantial protection to otherwise sensitive tissues against multiple agents, under conditions where one might expect considerable tumour killing. Furthermore, by a judicious choice of the resistance functions, combinations of agents that were previously proscribed because of their collateral toxicity, might become available and hence lead to enhanced tumour kill. In addition, a considerable selective advantage was conferred upon transgene-positive cells and selection for MDR1 expression resulted in co-selection of ATase-positive cells. From current experience in human trials of bone marrow gene therapy, the transduction frequency in haemopoietic stem cells will be low. 25 It may, therefore, be of great importance to be able to select transduced cells on the basis of expression of one or more drug resistance phenotypes. In preclinical experiments, both MDR1 and ATase have proved useful for selection of transduced cells in vivo. 10, 23, 26 Thus, using vectors such as SFMIH in a clinical setting, it is likely that following successive rounds of chemotherapeutic treatment with either an MDR1 substrate or an O 6 -alkylating agent, the protective effect of the gene therapy procedure would be enhanced.
Our results in a haemopoietic cell line provide important proof of principle for dual resistance to agents covered by MDR1-mediated multidrug resistance and O 6 -DNA-alkylating agents. Recent experiments have demonstrated that the resistance to chemotherapeutic agents of K562 cells transduced with a retrovirus encoding ATase is predictive of the resistance of similarly transduced human primary CD34
+ cells in vitro 12 and murine bone marrow progenitors in vivo. 11 Obviously, a more stringent test of the utility of this approach, in particular of the selection phenomenon, will arise from experiments in vivo, using mice reconstituted with SF1MIH-transduced bone marrow. Furthermore, in the light of the report by Bunting et al 28 of induction of a myeloproliferative disorder in mice transplanted with MDR1-transduced bone marrow, it will be important to investigate thoroughly the effects of SFMIH transduction on the haemopoietic compartment. Preliminary data obtained underline the dual utility of this vector for protecting primary myeloid cells in vivo from dose-limiting myelotoxicity. These data and further fine-tuning of the vector to achieve high titers and increase the genetic stability of the MDR1 cDNA 23 will provide the necessary impetus for the testing of the dual protection strategy in a clinical context.
